Seven Graduate From County Drug Treatment Court
May 18, 2010 – Judge Peggy Hora’s talk on Drug Treatment Courts in the 21st Century
Image by US Embassy New Zealand
Drug treatment courts are an excellent example of a successful deviation from established practice. They were created by sitting criminal court judges, overwhelmed and appalled by the real world they saw before them each day. Not only do drug treatment courts introduce new concepts and practices to the legal community, but they do so while protecting the defendant’s procedural and substantive rights.
Judge Peggy Hora retired from the California Superior Court after serving 21 years. She had a criminal assignment that included presiding over the Drug Treatment Court. She is a former dean of the B.E. Witkin Judicial College of California and has been on the faculty of the National Judicial College over 15 years. She is a recipient of the Bernard S. Jefferson Judicial Education Award from the California Judges’ Association and winner of the Rose Bird Award from California Women Lawyers. Judge Hora is a Senior Judicial Fellow for the National Drug Court Institute. She has lectured nationally and internationally and has written extensively on justice issues. The appellate court and over 100 journals and law reviews have cited her work. She is a 2009 Thinker in Residence appointed by the Premier of South Australia, where she is currently working on therapeutic jurisprudence and restorative justice issues for the government in Adelaide. Her most recent article, “Courting New Solutions Using Problem-Solving Justice: Key Components, Guiding Principles, Strategies, Responses, Models, Approaches, Blueprints and Tool Kits” will be published by the Chapman Law Review this spring.
Seven graduate from county drug treatment court
SAYRE — Seven people who struggled for years to get their lives back on track reached the culmination of a difficult journey Wednesday during the commencement of the Bradford County Drug Treatment Court, held at the Fortune Buffet in Athens Township.
Read more on Morning Times
Bayer’s rivaroxaban meets primary endpoint in long-term phase III EINSTEIN-DVT study
Bayer announced that a novel, convenient single-drug treatment approach with oral rivaroxaban met the primary efficacy endpoint of non-inferiority in the EINSTEIN-DVT phase III clinical trial and showed an overall relative risk reduction compared to the current standard therapy in the treatment of deep vein thrombosis (DVT) – initial enoxaparin treatment, followed by a vitamin K antagonist.
Read more on PharmaBiz